MK2 drives progression of pancreas and colon cancers by suppressing CD8⁺ T cell cytotoxic function and is a potential immunotherapy target

Medicine and Dentistry

• Drive 100%
• Cytotoxic T-Cell 100%
• Pancreas Cancer 100%
• Colon Carcinoma 100%
• Immunotherapy 100%
• Gastrointestinal Cancer 44%
• Immune Response 33%
• Immunocompetent Cell 33%
• In Vitro 22%
• Secretion (Process) 22%
• Tumor Microenvironment 22%
• Programmed Cell Death 22%
• Malignant Neoplasm 11%
• Carcinogenesis 11%
• Cancer Growth 11%
• Receptor 11%
• T Cell 11%
• Allograft 11%
• Tumor Cell 11%
• Immunosuppressive Treatment 11%
• Tumor Immunity 11%
• Real Time Polymerase Chain Reaction 11%
• Adoptive Transfer 11%
• Cell Killing 11%
• Tumor 11%
• Hyperactivation 11%
• Immunofluorescence 11%
• Inflammatory Cytokine 11%
• Protein Kinases 11%
• Mitogen-Activated Protein Kinase 11%
• Chemokine 11%
• Casein Kinase 11%
• Knockout Mouse 11%

Biochemistry, Genetics and Molecular Biology

• Colon 100%
• Drive 100%
• CD8 100%
• T Cell 100%
• Cytotoxic T Cell 100%
• Immunocompetent Cell 33%
• Immune Response 33%
• Secretion (Process) 22%
• Programmed Cell Death 22%
• Immunofluorescence 11%
• RAG1 11%
• Knockout Mouse 11%
• Tumor Immunity 11%
• Proinflammatory Cytokine 11%
• Real-Time Polymerase Chain Reaction 11%
• Cell Killing 11%
• Cell Composition 11%
• Protein Kinases 11%
• Carcinogenesis 11%
• Mitogen-Activated Protein Kinase 11%
• Chemokine 11%
• Casein Kinase 11%

Immunology and Microbiology

• Cytotoxic T-Cell 100%
• Colon 100%
• Pancreas 100%
• Immunotherapy 100%
• Immunocompetent Cell 33%
• Immune Response 33%
• Secretion (Process) 22%
• Programmed Cell Death 22%
• In Vitro 22%
• Mitogen 11%
• Immunosuppression 11%
• Knockout Mouse 11%
• Tumor Cell 11%
• Proinflammatory Cytokine 11%
• Tumor Immunity 11%
• Real Time Polymerase Chain Reaction 11%
• Cell Killing 11%
• Cell Composition 11%
• T Cell 11%
• Chemokine 11%
• Immunofluorescence 11%
• Allograft 11%
• Serine 11%
• Threonine 11%